TrialThe Lancet. Infectious diseases2022

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.

Peter G Kremsner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.